WELLMERA
LIVE

Serial Number

79148822

Owner

Wellmera AG

Attorney

Mark Lebow

Filing Date

Apr 16, 2014

Add to watchlist:

No watchlists yet
View on USPTO

WELLMERA Trademark

Serial Number: 79148822 • Registration: 4745656

WELLMERA is a trademark filed by Wellmera AG on April 16, 2014. The trademark is classified under Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Wellmera AG (2 trademarks)

Hochbergerstrasse 60B
CH-4057 Basel , CH

Entity Type: 99

Trademark Details

Filing Date

April 16, 2014

Registration Date

June 2, 2015

Published for Opposition

March 17, 2015

Cancellation Date

April 16, 2024

Goods & Services

Education and training services, namely, workshops and seminars in the field of branding, product valuation and pricing, healthcare, and economics; education and training services, namely, workshops and seminars in the field of design and facilitation of product value and strategy; workshops and seminars in the field of design and facilitation of product value; workshops and seminars in the field of economic strategies and support of health economic deliverables; workshops and seminars in the nature of training to instruct on planning, preparation, coordination and conducting of expert panels and advisory boards for presentations and briefing documents in the health care industry; training services in the field of facilitation of workshops with cross-functional teams and affiliates to develop and refine economic strategies and support the adaptation of health economic deliverables; and workshops and seminars in the field of cross-functional and regional applied health economics training

Software, namely, software for providing information on pricing and reimbursement assessments in health economic and market access strategies and plans in the health care industry

Advertising; commercial business management, and marketing and professional business consultancy; advertising products of third parties in the health care industry; business management, namely, marketing and professional consultation in pricing and reimbursement strategies for brands and products at all stages of lifecycle development; brand management for businesses; brand management for pharmaceutical and medical device companies; business management and consultation providing commercial and clinical commercial strategies and commercial strategies for the production of integrated evidence plans to support pricing, reimbursement and market access; commercial business management, namely, development of value strategies for internal communication with cross-functional teams and senior management of companies to facilitate internal decision making; commercial business management, namely, development of early pricing and reimbursement strategies for brands, product management consulting at all development stages, and licensing opportunities; commercial business management, namely, conducting of pricing and reimbursement landscape assessments; commercial business management, namely, conducting of competitor analyses and development of pathways for disease management for comparative effectiveness research planning; commercial business management, namely, development of payer objection handler documents identifying potential payer objections to product reimbursement and arguments to address them; preparation of briefing documents for payer advisory boards; commercial business management, namely, conducting qualitative small scale payer research for hypothesis generation and unbranded or branded payer message testing and validation; commercial business management, namely, providing placement for market access managers and directors; commercial business management, namely, development of health economics and outcomes research strategies to support internal communication with cross-functional teams and senior management to facilitate internal strategic decisions; commercial business management, namely, providing strategic support for the development of economic models; design and development of budget impact models; commercial business management, namely, development of actionable plans to support the value communication of a product; commercial business management, namely, planning, preparation, coordination and conducting of expert panels and advisory boards; planning and conducting of database-registry analyses

Scientific and technological services and research and design services relating thereto, namely, scientific and technological competitor analysis and developing pathways for disease management for competitive research planning, conducting qualitative payer research for hypothesis, testing and validation; design and development of computers and software; design and development of computers and software for third parties

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 8, 2024 DENA
DEATH OF INTERNATIONAL REGISTRATION
Nov 8, 2024 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Oct 24, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 25, 2022 INTS
INVALIDATION PROCESSED
Sep 23, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 17, 2022 INTR
CANCELLED SECTION 71
Dec 17, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 2, 2020 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 26, 2018 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 30, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 25, 2015 FICS
FINAL DISPOSITION PROCESSED
Sep 25, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 2, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 2, 2015 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 17, 2015 NPUB
PUBLISHED FOR OPPOSITION
Mar 17, 2015 PUBO
NOTIFICATION PROCESSED BY IB
Mar 13, 2015 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 25, 2015 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 25, 2015 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 25, 2015 NONP
ASSIGNED TO EXAMINER
Feb 25, 2015 DOCK
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 10, 2015 PREV
ASSIGNED TO LIE
Feb 9, 2015 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 23, 2015 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 23, 2015 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 23, 2015 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 23, 2015 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 23, 2015 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 19, 2014 GNFN
FINAL REFUSAL E-MAILED
Oct 19, 2014 GNFR
FINAL REFUSAL WRITTEN
Oct 19, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 19, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 19, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2014 TROA
REFUSAL PROCESSED BY IB
Aug 16, 2014 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 30, 2014 RFCS
REFUSAL PROCESSED BY MPU
Jul 30, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 30, 2014 RFCR
NON-FINAL ACTION WRITTEN
Jul 29, 2014 CNRT
ASSIGNED TO EXAMINER
Jul 28, 2014 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 22, 2014 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 16, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 11, 2014 REPR